Regeneron pauses studies of a key cancer drug, citing safety concerns,

The FDA put a partial clinical hold on the development program and asked Regeneron to revise its trial protocols to better control cases of cytokine …, The FDA put a partial clinical hold on the development program and asked Regeneron to revise its trial protocols to better control cases of cytokine …, Read More

Scroll to Top